Pharmacokinetics of nebulized and subcutaneously implanted terbinafine in cottonmouths (Agkistrodon piscivorus).

Ophidiomyces ophiodiicola, the causative agent of snake fungal disease, is proposed as a serious threat to the conservation of several snake populations. The objective of this study was to determine the pharmacokinetic parameters of terbinafine administered through nebulization and a sustained subcutaneous implant as potential treatments of Ophidiomyces in reptiles. Seven adult cottonmouths (Agkistrodon piscivorus) were used in single-dose trials. Each snake was nebulized with terbinafine (2 mg/ml) for 30 min and had blood collected before nebulization and up to 12 hr after nebulization. Following a 5-month washout, the same snakes were administered a subcutaneous implant containing 24.5 mg terbinafine; blood was collected at baseline, 1 day postimplant placement, and then once weekly for 9 weeks. Plasma for both studies was analyzed by high-performance liquid chromatography. The mean plasma concentrations of nebulized terbinafine peaked between 0.5 and 4 hr. The subcutaneously implanted terbinafine reached therapeutic concentrations on day 1 and maintained therapeutic for over 6 weeks. These methods and doses are recommended as potential treatment options for snake fungal disease in reptiles.

[1]  A. Arnold,et al.  OPHIDIOMYCES OPHIODIICOLA ON A CAPTIVE BLACK RACER (COLUBER CONSTRICTOR) AND A GARTER SNAKE (THAMNOPHIS SIRTALIS) IN PENNSYLVANIA , 2016, Journal of Zoo and Wildlife Medicine.

[2]  S. Chinnadurai,et al.  DISSEMINATED OPHIDIOMYCES OPHIODIICOLA INFECTION IN A CAPTIVE EASTERN MASSASAUGA (SISTRURUS CATENATUS CATENATUS) , 2016, Journal of Zoo and Wildlife Medicine.

[3]  A. Guthrie,et al.  Detection of Snake Fungal Disease Due to Ophidiomyces ophiodiicola in Virginia, USA , 2016, Journal of wildlife diseases.

[4]  Amelia G. White,et al.  Determining canine skin concentrations of terbinafine to guide the treatment of Malassezia dermatitis. , 2015, Veterinary dermatology.

[5]  K. McCurley,et al.  Experimental Infection of Snakes with Ophidiomyces ophiodiicola Causes Pathological Changes That Typify Snake Fungal Disease , 2015, mBio.

[6]  E. Driskell,et al.  Development of Snake Fungal Disease after Experimental Challenge with Ophidiomyces ophiodiicola in Cottonmouths (Agkistrodon piscivorous) , 2015, PloS one.

[7]  F. Gleason,et al.  The natural history, ecology, and epidemiology of Ophidiomyces ophiodiicola and its potential impact on free-ranging snake populations , 2015 .

[8]  C. Fontaine.  Long-term contraception in a small implant , 2015, Journal of feline medicine and surgery.

[9]  Michael J. Ravesi,et al.  First report of snake fungal disease from Michigan, USA involving Massasaugas, Sistrurus catenatus (Rafinesque 1818) , 2015 .

[10]  Xiaoling Wang,et al.  OPHIDIOMYCES OPHIODIICOLA DERMATITIS IN EIGHT FREE-RANGING TIMBER RATTLESNAKES (CROTALUS HORRIDUS) FROM MASSACHUSETTS , 2015, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[11]  P. Lotufo,et al.  Traditional Risk Factors Are More Relevant than HIV-Specific Ones for Carotid Intima-Media Thickness (cIMT) in a Brazilian Cohort of HIV-Infected Patients , 2015, PloS one.

[12]  J. Yarbrough,et al.  Determining Terbinafine in Plasma and Saline Using HPLC , 2015 .

[13]  K. Sladky,et al.  Pharmacokinetics of subcutaneous versus intramuscular administration of ceftiofur crystalline-free acid to bearded dragons (Pogona vitticeps). , 2014, American journal of veterinary research.

[14]  M. Allender,et al.  Systemic Ophidiomyces ophiodiicola Infection in a Free-Ranging Plains Garter Snake (Thamnophis radix) , 2014 .

[15]  P. Parejiya,et al.  Drug delivery to the nail: therapeutic options and challenges for onychomycosis. , 2014, Critical reviews in therapeutic drug carrier systems.

[16]  E. E. Evans,et al.  Pharmacokinetics of terbinafine after oral administration of a single dose to Hispaniolan Amazon parrots (Amazona ventralis). , 2013, American journal of veterinary research.

[17]  J. Wellehan,et al.  Selected emerging infectious diseases of squamata. , 2013, The veterinary clinics of North America. Exotic animal practice.

[18]  John W. Scott,et al.  Ongoing Health Assessment and Prevalence of Chrysosporium in the Eastern Massasauga (Sistrurus catenatus catenatus) , 2013, Copeia.

[19]  M. Souza,et al.  Pharmacokinetics of nebulized terbinafine in Hispaniolan Amazon parrots (Amazona ventralis). , 2012, Journal of avian medicine and surgery.

[20]  S. Cox,et al.  In Vitro Investigation of a Terbinafine Impregnated Subcutaneous Implant for Veterinary Use , 2012, Journal of drug delivery.

[21]  Z. Zeng,et al.  Single dose pharmacokinetics of terbinafine in cats , 2012, Journal of feline medicine and surgery.

[22]  T. Day,et al.  Terbinafine pharmacokinetics after single dose oral administration in the dog. , 2011, Veterinary dermatology.

[23]  M. Dreslik,et al.  Chrysosporium sp. Infection in Eastern Massasauga Rattlesnakes , 2011, Emerging infectious diseases.

[24]  B. Kukanich,et al.  Pharmacokinetics of oral terbinafine in horses and Greyhound dogs. , 2011, Journal of veterinary pharmacology and therapeutics.

[25]  P. de Backer,et al.  Voriconazole, a safe alternative for treating infections caused by the Chrysosporium anamorph of Nannizziopsis vriesii in bearded dragons (Pogona vitticeps). , 2010, Medical mycology.

[26]  R. Poppenga,et al.  Pharmacokinetics of Terbinafine After Single Oral Dose Administration in Red-Tailed Hawks (Buteo jamaicensis) , 2010, Journal of avian medicine and surgery.

[27]  R. Poppenga,et al.  Pharmacokinetics of Orally Administered Terbinafine in African Penguins (Spheniscus demersus) for Potential Treatment of Aspergillosis , 2010, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[28]  S. Krishnan-Natesan.  Terbinafine: a pharmacological and clinical review , 2009, Expert opinion on pharmacotherapy.

[29]  R. Li,et al.  Pharmacokinetics of Terbinafine in the Rabbit Ocular Tissues after Topical Administration , 2007, Ophthalmic Research.

[30]  M. Papich,et al.  PHARMACOKINETICS OF KETOPROFEN IN THE GREEN IGUANA (IGUANA IGUANA) FOLLOWING SINGLE INTRAVENOUS AND INTRAMUSCULAR INJECTIONS , 2006, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[31]  B. Pypendop,et al.  Pharmacokinetics of inhaled anesthetics in green iguanas (Iguana iguana). , 2006, American journal of veterinary research.

[32]  D. Samuelson,et al.  AN OUTBREAK OF FUNGAL DERMATITIS AND STOMATITIS IN A FREE-RANGING POPULATION OF PIGMY RATTLESNAKES (SISTRURUS MILIARIUS BARBOURI) IN FLORIDA , 2003, Journal of wildlife diseases.

[33]  A. McLachlan,et al.  Tissue distribution of terbinafine in rats. , 2001, Journal of pharmaceutical sciences.

[34]  Sanjeev Jain,et al.  Terbinafine, a unique oral antifungal: current perceptions , 2000, International journal of dermatology.

[35]  V. Sehgal,et al.  Onychomycosis: treatment perspective , 2000, International journal of dermatology.

[36]  C. L. Bennett,et al.  Itraconazole plasma and tissue concentrations in the spiny lizard (Sceloporus sp.) following once-daily dosing. , 1997, Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians.

[37]  J. Birnbaum.  Pharmacology of the allylamines. , 1990, Journal of the American Academy of Dermatology.